1 |
Nakahara, T., Yamanaka, K., Hatakeyama, S., Kita, A., Takeuchi, M., Kinoyama, I., Matsuhisa, A., Nakano, K., Shishido, T., Koutoku, H. and Sasamata, M. 2011. YM155, a novel Survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22, 454-462.
DOI
|
2 |
Nwizu, T., Ghi, M. G., Cohen, E. E. and Paccagnella, A. 2012. The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin. Radiat. Oncol. 22, 198-206.
DOI
|
3 |
Peng, X. H., Karna, P., Cao, Z., Jiang, B. H., Zhou, M. and Yang, L. 2006. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J. Biol. Chem. 281, 25903-25914.
DOI
|
4 |
Pizem, J., Cor, A. and Gale, N. 2004. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 45, 180-186.
DOI
|
5 |
Sarela, A. I., Macadam, R. C., Farmery, S. M., Markham, A. F. and Guillou, P. J. 2000. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645-650.
DOI
|
6 |
Seto, M., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P. and Korsmeyer, S. J. 1988. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 7, 123-131.
DOI
|
7 |
Shin, S., Sung, B. J., Cho, Y. S., Kim, H. J., Ha, N. C., Hwang, J. I., Chung, C. W., Jung, Y. K. and Oh, B. H. 2001. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40, 1117-1123.
DOI
|
8 |
Siegel, R., Naishadham, D. and Jemal, A. 2012. Cancer statistics. CA. Cancer J. Clin. 62, 10-29.
DOI
|
9 |
Simard, E. P., Torre, L. A. and Jemal, A. 2014. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 50, 387-403.
DOI
|
10 |
Su, L., Wang, Y., Xiao, M., Lin, Y. and Yu, L. 2010. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg. Oral Med. Oral. Pathol. Oral Radiol. Endod. 110, 484-491.
DOI
|
11 |
Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
|
12 |
Tirro, E., Consoli, M. L., Massimino, M., Manzella, L., Frasca, F., Sciacca, L., Vicari, L., Stassi, G., Messina, L., Messina, A. and Vigneri, P. 2006. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66, 4263-4272.
DOI
|
13 |
Yamanaka, K., Nakahara, T., Yamauchi, T., Kita, A., Takeuchi, M., Kiyonaga, F., Kaneko, N. and Sasamata, M. 2011. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res. 17, 5423-5431.
DOI
|
14 |
Zaffaroni, N., Pennati, M., Colella, G., Perego, P., Supino, R., Gatti, L., Pilotti, S., Zunino, F. and Daidone, M. G. 2002. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59,1406-1412.
DOI
|
15 |
Zhong, Q., Gao, W., Du, F. and Wang, X. 2005. Mule/ARFBP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.
DOI
|
16 |
Burri, R. J. and Lee, N. Y. 2009. Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev. Anticancer Ther. 9, 293-302.
DOI
|
17 |
Altieri, D. C. 2003. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54.
DOI
|
18 |
Ambrosini, G., Adida, C. and Altieri, D. C. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
DOI
|
19 |
Asechi, H., Hatano, E., Nitta, T., Tada, M., Iwaisako, K., Tamaki, N., Nagata, H., Narita, M., Yanagida, A., Ikai, I. and Uemoto, S. 2010. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int. J. Oncol. 37, 89-96.
|
20 |
Chandele, A., Prasad, V., Jagtap, J. C., Shukla, R. and Shastry, P. R. 2004. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6, 29-40.
DOI
|
21 |
Colnaghi, R., Connell, C. M., Barrett, R. M. and Wheatley, S. P. 2006. Separating the antiapoptotic and mitotic roles of survivin. J. Biol. Chem. 281, 33450-33456.
DOI
|
22 |
Duffy, M. J., O'Donovan, N., Brennan, D. J., Gallagher, W. M. and Ryan, B. M. 2007. Survivin: a promising tumor biomarker. Cancer Lett. 249, 49-60.
DOI
|
23 |
Marur, S. and Forastiere, A. A. 2008. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin. Proc. 83, 489-501.
DOI
|
24 |
Jung, K. W., Won, Y. J., Kong, H. J., Oh, C. M., Cho, H., Lee, D. H. and Lee, K. H. 2015. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res. Treat. 47, 127-141.
DOI
|
25 |
Kalavrezos, N. and Bhandari, R. 2010. Current trends and future perspectives in the surgical management of oral cancer. Oral Oncol. 46, 429-432.
DOI
|
26 |
Zhu, L., Fukuda, S., Cordis, G., Das, D. K. and Maulik, N. 2001. Anti-apoptotic protein suvivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett. 508, 369-374.
DOI
|
27 |
Kita, A., Nakahara, T., Yamanaka, K., Nakano, K., Nakata, M., Mori, M., Kaneko, N., Koutoku, H., Izumisawa, N. and Sasamata, M. 2011. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk. Res. 35, 787-792.
DOI
|
28 |
Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Brocker, E. B., Krammer, P. H. and Walczak, H. 2000. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 60, 553-559.
|
29 |
Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M. D., Rubini, C., Mariggio, M. A., Procaccini, M., Ferrari, F., De Rosa, G. and Altieri, D. C. 2003. Survivin expression in oral squamous cell carcinoma. Br. J. Cancer 89, 2244-2248.
DOI
|
30 |
Marioni, G., Bertolin, A., Giacomelli, L., Marchese-Ragona, R., Savastano, M., Calgaro, N., Marino, F., De Filippis, C. and Staffieri, A. 2006. Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res. 26, 3813-3817.
|
31 |
Molin, Y. and Fayette, J. 2011. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 22, 621-625.
DOI
|
32 |
Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Hatakeyama, S., Kinoyama, I., Matsuhisa, A., Kudoh, M. and Sasamata, M. 2007. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormonerefractory prostate tumor xenografts. Cancer Res. 67, 8014-8021.
DOI
|
33 |
Morgillo, F., Martinelli, E., Troiani, T., Orditura, M., De Vita, F. and Ciardiello, F. 2011. Antitumor activity of Sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine. Kinase Inhibitors. PLoS One 6, e28841.
DOI
|